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Recent studies have demonstrated that in addition to their antimicrobial activity, cationic host defense
peptides, like the human cathelicidin LL-37, perform many activities relating to innate immunity, including the
induction or modulation of chemokine and cytokine production, alteration of gene expression in host cells, and
inhibition of proinflammatory responses of host cells to bacterial components such as lipopolysaccharide
(LPS) in vitro and in vivo. To investigate if these properties are shared by smaller peptides, two cathelicidin
peptides derived from bovine neutrophils, the 13-mer indolicidin and Bac2A, a linear 12-amino-acid derivative
of bactenecin, were compared to the 37-amino-acid peptide LL-37. Indolicidin, like LL-37, inhibited LPS-
induced tumor necrosis factor alpha (TNF-) secretion, even when added up to an hour after the addition of
Escherichia coli O111:B4 LPS to the human macrophage/monocyte-like THP-1 cell line. In contrast, Bac2A
demonstrated no significant antiendotoxin activity. At low concentrations, indolicidin and LL-37 acted syner-
gistically to suppress LPS-induced production of TNF-. Indolicidin was analogous to LL-37 in its ability to
induce the production of the chemokine interleukin-8 (IL-8) in a human bronchial cell line, 16HBE14o, but
it was unable to induce production of IL-8 in THP-1 cells. In contrast, Bac2A was unable to induce IL-8 in
either cell type. Conversely, Bac2A was chemotactic for THP-1 cells at concentrations between 10 and 100
g/ml, while indolicidin and LL-37 were not chemotactic at these concentrations for THP-1 cells. This indicates
that in addition to the potential for direct microbicidal activity, cationic host defense peptides may have diverse
and complementary abilities to modulate the innate immune response.
Cationic antimicrobial peptides are conserved across virtu-
ally all forms of life as a primitive component of the innate
immune response. They can be expressed either constitutively
or in response to pathogen-associated molecular pattern mol-
ecules, such as bacterial lipopolysaccharide (LPS), or inflam-
matory mediators, such as interleukin 6 (IL-6) and tumor ne-
crosis factor alpha (TNF-) (6, 41). Although they can be
potent antimicrobial agents, a key element of their therapeutic
potential may involve the myriad of other activities attributed
to them (25). Indeed, some peptides such as the human cathe-
licidin LL-37 have been proposed to have far more potent
immunomodulatory activities than antimicrobial functions (1,
24). When considering the use of peptides like LL-37 in im-
munotherapy, one must take into account the large size of this
peptide and the corresponding issues this raises, including cost
of goods, protease lability, and pharmacokinetics. In this study,
we investigated the immunomodulatory properties of two of
the smallest known active peptides, both derived from bovine
cathelicidins, and contrasted those activities to LL-37, a known
immunomodulator, with the goal of developing novel immu-
nomodulatory therapies.
Naturally occurring cationic peptides can vary in size from
12 to 50 amino acids and have the property of folding into
amphipathic structures (often after contact with membranes)
that have a positively charged hydrophilic face and a hydro-
phobic face. In humans, the major linear peptide is the sole
cathelicidin characterized to date, LL-37. LL-37 is the proteo-
lytically processed extracellular form of hCAP-18, a cathelici-
din peptide which is constitutively produced in the secondary
granules of neutrophils and by a variety of other cells. Al-
though found at mucosal surfaces at concentrations of around
2 g/ml, its expression is induced upon exposure to proinflam-
matory mediators or during the course of infection or inflam-
mation in a variety of tissues (1, 14, 20, 36). Although cathe-
licidins are not well conserved between species, the
evolutionary relationship between these peptides can be in-
ferred from the highly conserved proregion called the cathelin
domain that is cleaved to release the active peptide. Catheli-
cidins have been found in cows (BMAP-27, indolicidin, and
bactenecin), pigs (protegrins), mice (CRAMP), rabbits
(CAP18) and humans (hCAP-18/LL-37), and this evolutionary
conservation suggests an important role in innate immunity
(reviewed in reference 40). To date, studies of the influence of
peptides as effectors of innate immunity have tended to utilize
larger peptides of 26 amino acids or more in size (9). In this
study, two of the shortest known peptides, indolicidin and
Bac2A, a derivative of bactenecin, were investigated for their
ability to affect a variety of innate immune responses such as
cytokine production, antiendotoxin activity, and chemotaxis.
Indolicidin, a 13-amino-acid, proline- and tryptophan-rich
cathelicidin, folds into a characteristic boat-shaped structure
when associated with membranes (23). Its moderate antimi-
crobial activity (MICs of between 16 and 64 g/ml for common
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gram-negative bacteria and between 4 and 8 g/ml for gram-
positive bacteria) and its ability to interact with microbial
membranes have been well characterized (7). Bactenecin is a
12-amino-acid cathelicidin that is also moderately active
against many common gram-negative pathogens (MICs of ap-
proximately 8 g/ml) and gram-positive bacteria (MICs of 64
g/ml or greater). The functional structure of bactenecin in
vivo has not been well characterized, and there is some evi-
dence for a linear structure (38). Bac2A is a linearized deriv-
ative of bactenecin in which two cysteine residues have been
replaced with two alanine residues. It has modest broad-spec-
trum activity, with MICs of between 2 and 32 g/ml for gram-
negative bacteria and between 0.25 and 16 g/ml for gram-
positive bacteria, that is consistent with the activity of the
disulfide-bonded peptide (22). This modification prevents the
possibility of concatemer formation, thus making Bac2A a bet-
ter target for drug development.
Previous research has shown that LL-37 is a potent immu-
nomodulator. LL-37 has been demonstrated to be a chemoat-
tractant for human monocytes, T cells (5), and mast cells (18);
is a potent antiendotoxic agent (27); and induces chemokine
production (24). In light of these observations, we compared
the immunomodulatory activities of the two bovine cathelici-
dins, indolicidin and Bac2A, to those of the better-character-
ized LL-37 with respect to antiendotoxin properties, chemo-
taxis, and chemokine production. We found that indolicidin
and Bac2A have different immunomodulatory properties,
which make them candidates for development as novel thera-
pies.
MATERIALS AND METHODS
Cell lines and culture conditions. The human monocyte-like cell line THP-1
(33) was obtained from the American Type Culture Collection (Rockville, MD)
(ATCC TIB-202) and grown in supplemented RPMI 1640 medium containing
10% fetal calf serum and 1% L-glutamine (Gibco BRL, Burlington, Ontario,
Canada). THP-1 cells were differentiated into adherent macrophage-like cells by
the addition of 100 mM phorbol myristate acetate and incubation at 37°C in 5%
CO2 for 3 days as described previously (32). Undifferentiated THP-1 monocytes
were used for the chemotaxis experiments. Differentiated macrophage-like cells
were used for the antiendotoxin assays. The human bronchial epithelial cell line
16HBE14o (HBE) was a gift from D. Gruenert (Cardiovascular Research
Institute, University of California) (4) and was maintained in minimal essential
medium (MEM) with Earle’s salts (Gibco BRL, Burlington, Ontario, Canada).
HBE cells were maintained in flasks and seeded into wells that had been treated
with mouse type 4 collagen and human fibronectin solution (8.5 ml minimal
essential medium with Earle’s salts, 100 l fibronectin, 100 l collagen, and 1 ml
of 1 mg/ml bovine serum albumin; Gibco BRL, Burlington, Ontario, Canada).
Peptide synthesis. All peptides were synthesized by N-(9-fluorenyl) methoxy-
carbonyl chemistry at the Nucleic Acid/Protein Service unit at the University of
British Columbia, as previously described (10). Peptides were purified by reverse-
phase high-performance liquid chromatography and were at least 98% pure. The
concentration of the peptides in solution was determined by amino acid analysis.
Cytotoxicity assay. An MTT assay (American Type Culture Collection) was
used to assess the cytotoxicity of the peptides and was performed as per the
manufacturer’s instructions. The assay is based on the cleavage of the yellow
tetrazolium salt MTT into purple formazan by metabolically active cells. Cells
were cultured as described above, and peptides were added for 24 h. A decrease
in the absorbance at 550 nm indicated a decrease in cell viability.
Cytokine production. IL-8 or TNF- found in the supernatants of the treated
cells was measured using commercially prepared enzyme-linked immunosorbent
assay (ELISA) plates in accordance with the manufacturer’s suggestion (R&D
systems, Minneapolis, MN). Cells were seeded in 24-well tissue culture plates at
a concentration of 2  105 cells/ml (THP-1) or 5  105 cells/ml (HBE) and
incubated for either 3 days (THP-1) or 48 h (HBE). Cells were then incubated
at least in triplicate for 6 hours (to measure TNF- production) or 8 hours (to
measure IL-8 production) either in the presence of medium alone or with
Escherichia coli O111:B4 LPS (Sigma Chemical Co., St Louis, Mo.), cationic
peptides, or a combination of LPS and peptide (concentrations are stated in the
text) in medium. Supernatants were collected and stored at 20°C until use.
Chemotaxis assay. Chemotaxis of the monocyte-like cell line THP-1 was
assayed with a 96-well disposable chemotaxis system with 5-m polycarbonate
filters (Chemotx; Neuroprobe, Gaithersburg, MD). Chemotactic factors were
diluted in RPMI medium supplemented with 1% bovine serum albumin (che-
motaxis medium) and added to the bottom chamber of the chemotaxis plate. A
106-cell/ml solution of THP-1 cells was made in chemotaxis medium, and 50 l
was added to the top of the chamber. The plate was incubated at 37°C in 5% CO2
for 3 hours. In order to quantify the number of cells that migrated through the
filter, a standard curve of cell number represented by color change was created
using a colorimetric assay of cell viability based on cleavage of tetrazolium salt
WST-1 (Roche Diagnostics). WST-1 (10%, vol/vol) was added, and the plate was
incubated at 37°C in 5% CO2 until color development was complete. The plate
was then read at 570 nm with a PowerWave 340 ELISA plate reader. The
number of cells that had migrated through the membrane was expressed as a
percentage of the total number of cells added (chemotaxis index).
Statistical analysis. Student’s t test was performed to determine statistical
significance. Values are expressed as means  standard errors. Significance was
determined as a P value of 0.05.
RESULTS
Indolicidin, Bac2A, and LL-37 are not cytotoxic at concen-
trations used in this study. Cytotoxicity was assessed using the
MTT assay. None of the peptides caused significant cytotoxic-
ity in either the HBE or THP-1 cell line at concentrations of
100 g/ml (Fig. 1). In contrast, the cytotoxic peptide CP29
caused significant cell death at a concentration of 50 g/ml
(data not shown).
Indolicidin, but not Bac2A, displays potent antiendotoxic
properties. Certain cationic peptides have the ability to block
the production of cytokines produced in response to LPS by
either directly up-regulating inhibitory pathways in cells (26) or
interfering with the ability of LPS to bind LPS-binding protein
(27). THP-1 cells were stimulated with E. coli LPS, and the
FIG. 1. LL-37, Bac2A, and indolicidin are not cytotoxic to THP-1
cells (A) or HBE cells (B) at concentrations 100 g/ml. At 300
g/ml, significant cytotoxicity was observed in indolicidin-treated HBE
cells and in indolicidin- and LL-37-treated THP-1 cells. Mean values
standard errors of the mean of three independent experiments are
represented. A Student’s t test was performed, and asterisks denote
significance at a P value of 0.005 compared to cells treated with a
vehicle control only.
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amount of TNF- in the supernatant was assayed by ELISA.
The cells produced between 2,600 and 3,900 ng/ml of TNF-.
The ability of the short peptides indolicidin and Bac2A to
inhibit LPS-induced TNF- production in the THP-1 cell line
was investigated at low concentrations of host defense peptides
such as would be found at mucosal surfaces. The addition of
indolicidin at the same time as LPS suppressed the LPS-in-
duced production of TNF- in a dose-dependent manner (Fig.
2) in the differentiated macrophage-like THP-1 cell line and
was statistically significant at 5 g/ml (P  0.001). This in-
hibition was not as potent at low concentrations as was ob-
served for LL-37 (Fig. 2), a human cathelicidin previously
shown to have antiendotoxin ability (27); however, at concen-
trations of 50 g/ml, over 80% inhibition was observed (data
not shown). In contrast, Bac2A caused no inhibition over the
concentration range of 1 to 10 g/ml and demonstrated only
moderate antiendotoxin activity (approximately 30%) at 20
g/ml. Interestingly, as shown previously with LL-37 and the
insect-derived peptide CEMA (10, 24), the inhibition of cyto-
kine production was observed even when indolicidin was added
to the THP-1 cells up to 1 hour after LPS (data not shown).
This indicates that the antiendotoxin properties of indolicidin
may be due to an interaction of the peptide with cells in
addition to direct neutralization of LPS.
The antiendotoxin activity of indolicidin and LL-37 in com-
bination is greater than that of the additive effect. It has been
well established that certain cationic peptides used in combi-
nation can demonstrate synergistic antimicrobial activity (39).
To determine whether this phenomenon was applicable to the
nonantimicrobial activities of cationic peptides, we examined
the ability of LL-37 to work synergistically with indolicidin to
inhibit LPS-induced TNF- production. The antiendotoxin ac-
tivity of indolicidin and LL-37 in combination was significantly
greater than that of either peptide alone and greater than that
of the additive effect of these two peptides (Fig. 3) (P  0.05).
In contrast, the addition of human cationic peptides such as
human neutrophil peptide 1 or human beta defensins 1 and 2
with either indolicidin or LL-37 produced an additive rather
than a synergistic effect (data not shown).
Bac2A is a more potent chemotactic agent than indolicidin.
It has been shown previously that LL-37 is chemotactic for
various cells types, including monocytes, mast cells, and T cells
(5, 19). Little is known about the chemoattractant properties of
other cathelicidins, although a relative of bactenecin, Bac7, has
been shown to chemoattract monocytes (35). In this experi-
ment, the abilities of indolicidin, Bac2A, and LL-37 to induce
chemotaxis of undifferentiated THP-1 cells were investigated.
The addition of Bac2A to the bottom chamber of the Neuro-
probe Chemotx filter induced the migration of THP-1 cells in
a statistically significant (P  0.05 at 10 g/ml Bac2A and P 
0.001 at 50 g/ml Bac2A) and dose-dependent manner (Fig.
4). Indolicidin did not induce a statistically significant increase
in chemotaxis, except at a concentration of 300 g/ml, at which
concentration it demonstrated some cytotoxicity. Interestingly,
LL-37, which has previously been shown to be chemotactic for
blood-derived monocytes (5), was not chemotactic for THP-1
cells.
Indolicidin, but not Bac2A, can induce IL-8 expression in
16HBE4o cells. It has been shown previously that LL-37
induces the release of the chemokines IL-8 and/or MCP-3 in
both the murine lung and various cell lines (24). Therefore, we
investigated the possibility that indolicidin and/or Bac2A might
have similar properties. In differentiated THP-1 cells, indolici-
din inhibited the LPS-induced production of the cytokine
TNF- but did not itself induce TNF- or IL-8 (data not
FIG. 2. Dose-dependent inhibition of LPS-induced TNF- by ad-
dition of peptides. Indolicidin and LL-37 significantly reduced the
amount of TNF- produced by differentiated THP-1 cells upon stim-
ulation with 100 ng/ml of E. coli O111:B4 LPS. Bac2A did not reduce
the amount of TNF- at the concentrations tested (N/D, no detectable
decrease in TNF-). Mean values standard error of the mean of one
representative experiment of at least three are represented. A Stu-
dent’s t test was performed, and asterisks denote significance at a P
value of 0.001 compared to controls treated with LPS only.
FIG. 3. The addition of indolicidin and LL-37 in combination pro-
duces a greater-than-additive inhibition of LPS-induced TNF-. In-
dolicidin and LL-37 significantly reduced the amount of TNF- pro-
duced by differentiated THP-1 cells upon stimulation with 100 ng/ml of
E. coli O111:B4 LPS. The combination of very small amounts of
indolicidin (1 g/ml) or LL-37 (1 g/ml or 100 ng/ml) resulted in a
greater reduction of LPS-induced TNF- than would be predicted to
occur if this effect was strictly additive. Mean values of the averages of
three independent experiments  the standard error of the mean are
shown. A one-tailed Student’s t test was performed, and the results
significant at a P value of 0.05 are marked with an asterisk.
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shown). However, in the human bronchial cell line 16HBE4o,
indolicidin concentrations of 10 g/ml induced significant
production of the chemokine IL-8 (P  0.05) in a dose-depen-
dent manner (Fig. 5) but did not induce TNF- (data not
shown). Bac2A did not induce any cytokine or chemokine
production, even at 50 g/ml (data not shown).
DISCUSSION
In this study, the bovine neutrophil-derived peptides in-
dolicidin and Bac2A were demonstrated to have diverse and
complementary immunomodulatory functions, as summarized
in Table 1, in addition to their established antimicrobial activ-
ities. Indolicidin inhibited the LPS-induced proinflammatory
cytokine responses in a macrophage-like cell line and induced
chemokine production in a dose-dependent manner in a bron-
chial epithelial cell line. Conversely, Bac2A had very weak
antiendotoxic or chemokine-inducing properties but acted di-
rectly to induce chemotaxis of macrophage-like THP-1 cells.
Cationic peptides have traditionally been studied as antimi-
crobial agents. In bovine neutrophils, multiple classes of pep-
tides have been found, including the -sheet defensins (30),
the -helical peptide BMAP, and the short (12 to 13 amino
acids) cationic peptides bactenecin (8) and indolicidin (29). It
seems reasonable to assume that these peptides have evolved
to work in combination as opposed to independently and that
each peptide has distinct (but possibly overlapping) functions.
Indeed, -defensins have different antimicrobial activity spec-
tra (31), while certain combinations of peptides have been
demonstrated to be synergistic in their antimicrobial activities
(39). However, direct killing of microbes may not always be the
primary role that these agents perform in the innate immune
response, as the physiological concentrations of peptides and
of antagonistic monovalent and divalent cations are often dif-
ficult to rationalize with a primary antimicrobial role in vivo (1,
11) Alternatively, their possible primary action is modulation
of immune mechanisms, as these functions occur at physiolog-
ical salt and peptide concentrations (1, 24). However, the de-
gree to which these functions contrast and/or complement each
other in different host defense peptides is largely unknown.
Individual peptides have been demonstrated to have partic-
ular activities in modulating aspects of innate immunity, al-
though a thorough evaluation of the immunomodulatory ef-
fects of most cationic peptides has not been made. To test the
possibility that different peptides may have diverse immuno-
modulatory functions on human cells and thus have alterna-
tively directed potential as immune-boosting drugs, we chose
to evaluate the properties of two of the smallest related cat-
ionic peptides. It was interesting that Bac2A, despite having a
stronger binding affinity than indolicidin for LPS (27), was
unable to block LPS-induced TNF- production at equivalent
concentrations. This was consistent with our previous results
indicating that the ability of peptides to block LPS-induced
responses does not rely entirely on their ability to bind to LPS
(28). Indeed, gene array studies on the RAW 264.7 mouse
macrophage cell line demonstrated that peptides can block the
expression of only a subset of the genes induced by LPS, while
themselves inducing the expression of a unique subset of genes
(26). This is consistent with the interpretation that the addition
of peptides does not merely prevent LPS from binding to the
macrophages but alters LPS-induced gene expression in a
more directed fashion. Indeed, we showed that indolicidin can
block cytokine production when added up to an hour after the
addition of LPS to cells (data not shown) as previously dem-
onstrated for LL-37 and the insect peptide CEMA. In this time
period, we assume that LPS would already bind to LPS recep-
tors on macrophages and initiate signaling (12). The ability of
peptides to selectively block proinflammatory cytokine gene
expression implies that although their ability to bind to LPS
and disrupt LPS binding to LPS-binding protein (27) may be a
component of their antiendotoxin ability, it is not the sole
method by which they block proinflammatory responses. In-
deed, among the genes that are up-regulated directly by pep-
tides are antiinflammatory cytokines such as IL-10 (24).
The ability of peptides to block the excess cytokine produc-
FIG. 4. Bac2A is a more potent chemoattractant for undifferenti-
ated THP-1 cells than indolicidin. Indolicidin, Bac2A, LL-37, or water
(vehicle control) was added to the bottom well of a chemotaxis cham-
ber at the concentrations shown. Undifferentiated THP-1 cells were
added to the top well, and after 3 hours, chemotaxis was assessed.
Chemotaxis was measured by calculating the total number of cells that
migrated as a percentage of the total number of cells added. Mean
values of the averages of three independent experiments  the stan-
dard error of the mean are shown. A two-tailed t test was performed,
and the results significant at a P value of 0.05 are marked with an
asterisk, and those significant at a P value of 0.001 are marked by a
double asterisk.
FIG. 5. Indolicidin induces IL-8 production in a dose-dependent
manner in the human bronchial epithelial cell line 16HBE4o. Cells
were grown to confluency and subsequently incubated with indolicidin
for 8 hours. The presence of IL-8 in the supernatant was detected by
ELISA. Mean values  standard errors of the means of one represen-
tative experiment of at least three are represented (n	 4 replicates for
each condition). A two-tailed t test was performed, and results signif-
icant at a P value of 0.05 are marked with an asterisk.
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tion that is a hallmark of sepsis has led to their consideration
as antisepsis agents (3, 13, 17). However, toxicity due to the
relatively high concentrations of peptide required is a major
concern. In this study, we demonstrate that low concentrations
of multiple peptides may be more effective in blocking LPS-
induced cytokine responses than higher concentrations of a
single peptide and that exogenous addition of peptides might
lead to synergy with the host’s own naturally occurring pep-
tides.
It has been postulated that antimicrobial peptides have
evolved from the deletion products of CXC chemokines (15),
and, consistent with this, certain peptides have been shown to
be chemotactic for distinct subsets of leukocytes. For example,
LL-37 has been shown to be chemotactic for human blood-
derived monocytes and T cells (5) through formyl peptide
receptor-like 1 (FPRL1) at concentrations of approximately 50
g/ml, whereas it is chemotactic towards mast cells through
two different receptors between 5 and 10 g/ml (18). Thus,
chemotaxis occurs at concentrations that are generally higher
than those required for antiendotoxin activity. Although there
is a paucity of data indicating the exact concentrations of host
defense peptides in vivo, it is known that the cathelicidins are
found at extremely high concentrations in the granules of neu-
trophils, and it seems reasonable that chemotaxis in vivo might
occur in response to somewhat higher concentrations of pep-
tides, such as would occur at sites of neutrophil degranulation.
Interestingly, in our study, LL-37 was not chemotactic for the
THP-1 monocyte-like cell line (Fig. 4) even though this cell
line has been shown to express FPRL-1 (21), and we found that
these cells express FPRL-1 at the reverse transcriptase PCR
level (unpublished results). Conversely, Bac2A, but not in-
dolicidin, was shown to induce chemotaxis of the cells at con-
centrations of 10 g/ml (Fig. 3). Future experiments will
elucidate the chemotactic receptor for Bac2A.
These data indicate that short peptides such as indolicidin
and Bac2A possess contrasting immunomodulatory properties
which appear to be comparable to certain activities of the
known immunomodulator LL-37. Interestingly, these bovine-
derived peptides function on human cell lines, indicating that
host defense peptides may demonstrate conserved function
across species. The differences in their immunomodulatory
properties may reflect physiologically complementary func-
tions in vivo and/or be a consequence of the modifications
made to the naturally occurring bactenecin to produce the
derivative Bac2A. Regardless of this, these contrasting activi-
ties make these peptides valuable in the design of alternatively
directed therapeutic agents and as tools in dissecting the vari-
ations in the mechanisms that underpin these diverse activities.
In addition, their smaller size compared to LL-37 makes them
potentially exciting prototypes for development as novel im-
munomodulatory drugs, especially since their collective ability
to enhance chemokine production, induce chemotaxis, and
block endotoxin responses resembles the properties of LL-37.
Future work will involve optimizing these peptides and better
characterizing their immunomodulatory properties to further
illuminate their potential as novel therapeutic agents.
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